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Abstract Different adiposity measures have been associ-
ated with increased risk of atrial fibrillation, however,
results have previously only been summarized for BMI.
We therefore conducted a systematic review and meta-
analysis of prospective studies to clarify the association
between different adiposity measures and risk of atrial
fibrillation. PubMed and Embase databases were searched
up to October 24th 2016. Summary relative risks (RRs)
were calculated using random effects models. Twenty-nine
unique prospective studies (32 publications) were included.
Twenty-five studies (83,006 cases, 2,405,381 participants)
were included in the analysis of BMI and atrial fibrillation.
The summary RR was 1.28 (95% confidence interval:
1.20–1.38, I2 = 97%) per 5 unit increment in BMI, 1.18
(95% CI: 1.12–1.25, I2 = 73%, n = 5) and 1.32 (95% CI:
1.16–1.51, I2 = 91%, n = 3) per 10 cm increase in waist
and hip circumference, respectively, 1.09 (95% CI:
1.02–1.16, I2 = 44%, n = 4) per 0.1 unit increase in waist-
to-hip ratio, 1.09 (95% CI: 1.02–1.16, I2 = 94%, n = 4)
per 5 kg increase in fat mass, 1.10 (95% CI: 0.92–1.33,
I2 = 90%, n = 3) per 10% increase in fat percentage,
1.10 (95% CI: 1.08–1.13, I2 = 74%, n = 10) per 5 kg
increase in weight, and 1.08 (95% CI: 0.97–1.19,
I2 = 86%, n = 2) per 5% increase in weight gain. The
association between BMI and atrial fibrillation was non-
linear, pnonlinearity\ 0.0001, with a stronger association at
higher BMI levels, however, increased risk was observed
even at a BMI of 22–24 compared to 20. In conclusion,
general and abdominal adiposity and higher body fat mass
increase the risk of atrial fibrillation.
Keywords Obesity  BMI  Waist circumference  Hip
circumference  Waist-to-hip ratio  Fat mass  Fat
percentage  Atrial fibrillation  Meta-analysis
Introduction
The prevalence of overweight and obesity has increased
rapidly over the last decades in all areas of the world [1].
Overweight and obesity are important risk factors for a
wide range of chronic diseases, including cardiovascular
diseases, type 2 diabetes, gallbladder disease, total mor-
tality and several types of cancer [2–11], and the current
trends are a major challenge for public health both in terms
of reduced quality of life and increased medical costs [12].
Atrial fibrillation is the most common arrhythmia
diagnosed in clinical practice [13] and globally there was
an estimated 5 million incident cases in 2010 [14], while
the prevalence was estimated at 33 million in 2015 [15].
The prevalence of atrial fibrillation has been projected to
increase 2.5-fold in the next 50 years, mainly due to an
aging population, but also due to an increased incidence of
the disease [13]. Patients with atrial fibrillation are at
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increased risk of cardiovascular diseases including
ischemic heart disease, heart failure, sudden cardiac death,
stroke, as well as chronic kidney disease and all cause
mortality [16]. The economic costs due to atrial fibrillation
in the US has been estimated at more than $6 billion
annually [17]. Overweight and obesity have been associ-
ated with increased risk of atrial fibrillation in several
studies [18, 19]. Some studies suggested a J-shaped dose–
response relationship between BMI and atrial fibrillation
[20, 21], however, other studies suggested a linear associ-
ation [22–28]. In addition, it is not clear whether other
measures of body fatness such as waist circumference
[26, 29–32], hip circumference [30, 32, 33], waist-to-hip
ratio [29, 30, 32, 33], fat mass [30–32, 34], or body fat
percentage [30, 31, 34] are associated with risk of atrial
fibrillation or if the association differs by geographic
location or ethnicity. Although a meta-analysis from 2008
found that both overweight and obesity as measured by
body mass index (BMI) was associated with increased risk
of atrial fibrillation [35], at least 20 additional studies
involving[78,000 atrial fibrillation cases and[2.2 million
participants have been published since that meta-analysis
[20, 21, 23–31, 33, 34, 36–42]. Given the large number of
additional studies that have been published since the pre-
vious meta-analysis and the availability of data regarding
other adiposity measures as well, we conducted a system-
atic review and dose–response meta-analysis of prospective
studies that investigated the association between body mass
index, waist circumference, waist-to-hip ratio, or other
measures of adiposity (hip circumference, fat mass, weight,
weight gain) and the risk of atrial fibrillation.
Methods
Search strategy and inclusion criteria
We searched the PubMed and Embase databases up to
October 24th 2016 for eligible studies (DA, SS and AS). A
list of the search terms used are provided in Supplementary
Tables 1 and 2. We followed standard criteria (MOOSE
Guidelines) for reporting meta-analyses [43]. In addition,
we searched the reference lists of previous meta-analyses
[2, 35, 44] and the reference lists of the relevant publica-
tions for further studies. Study quality was assessed using
the Newcastle–Ottawa scale [45].
Study selection
We included prospective and retrospective cohort studies
and nested case–control studies of the association between
adiposity measures (BMI, waist circumference, and waist-
to-hip ratio, hip circumference, body fat mass, fat
percentage, weight, weight gain) and risk of atrial fibril-
lation that were published in English. Studies in high-risk
populations (patient populations), abstract only publica-
tions, grey literature and unpublished studies were exclu-
ded. Adjusted relative risk (RR) estimates (hazard ratios,
risk ratios, or odds ratios) had to be available with the 95%
confidence intervals (95% CIs) in the publication and for
the dose–response analysis, a quantitative measure of adi-
posity and the total number of cases and person-years or
non-cases for at least 3 categories of the adiposity variable
or on a continuous scale had to be available in the publi-
cation. When multiple publications were available from the
same study we used the study with the largest number of
cases, but when data on different anthropometric measures
were covered by different publications from the same study
both were included, but each study was only included once
in each analysis. A list of the excluded studies and exclu-
sion reasons are found in the Supplementary Table 3.
Data extraction
We extracted the following data from each study: The first
author’s last name, publication year, country where the
study was conducted, study period, sample size, number of
cases/controls, exposure variable, exposure level, relative
risks and 95% confidence intervals for the highest versus
the lowest level of the exposure variable and variables
adjusted for in the analysis. Data were extracted by one
reviewer (DA) and checked for accuracy by a second
reviewer (AS).
Statistical analysis
We calculated summary RRs and 95% CIs for a 5 unit
increment in BMI, 10 cm increment in waist and hip cir-
cumference, a 0.1 unit increment in waist-to-hip ratio, and
a 5 kg increment in fat mass and weight, 10% increase in
body fat percentage, and 5% increase in weight gain using
a random effects model [46]. For the primary analysis we
used the model from each study that had the greatest degree
of control for potential confounding with the exception of
when potential intermediate risk factors were adjusted for
in a separate step (as an exploration of how much of the
association might be mediated by cholesterol for example).
The average of the natural logarithm of the RRs was esti-
mated and the RR from each study was weighted according
to the method of DerSimonian and Laird [46]. A two-tailed
p\ 0.05 was considered statistically significant. If studies
reported results separately for men and women or other
subgroups we combined the subgroup-specific estimates
using a fixed-effects model to generate an overall estimate
so that each study was only represented once in the main
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analysis, but sex-specific results are presented separately in
subgroup analyses.
The method described by Greenland and Longnecker
[47] was used for the dose–response analysis and we cal-
culated study-specific slopes (linear trends) and 95% CIs
from the natural logs of the reported RRs and CIs across
categories of each adiposity measure. The mean or median
level of each adiposity measure in each category was
assigned to the corresponding relative risk for every study
and for studies that reported the exposures in ranges we
calculated the average of the upper and the lower cut-off
point which was used as a midpoint. When the lowest or
highest category was open-ended or had an extreme range
we used the width of the adjacent interval to calculate an
upper or lower confidence interval. A potential nonlinear
dose–response relationship between BMI and waist cir-
cumference and risk of atrial fibrillation was examined by
using fractional polynomial models [48]. We determined
the best fitting second order fractional polynomial regres-
sion model, defined as the one with the lowest deviance. A
likelihood ratio test was used to assess the difference
between the nonlinear and linear models to test for non-
linearity [48].
Subgroup analyses stratified by sex, measurement versus
self-report of adiposity measures, duration of follow-up,
geographic location, number of cases, study quality scores,
and adjustment for confounders (age, smoking, alco-
hol, and physical activity) and potential intermediates
(hypertension, blood pressure, cholesterol, diabetes melli-
tus, coronary heart disease, heart failure, and left ventric-
ular hypertrophy) were conducted to investigate potential
sources of heterogeneity and heterogeneity between studies
was quantitatively assessed by the Q test and I2 [49]. Meta-
regression analyses were used to examine between sub-
group differences in the summary estimates. Small study
effects, such as publication bias, were assessed by
inspecting the funnel plots for asymmetry and with Egger’s
test [50] and Begg’s test [51] with the results considered to
indicate small study effects when p\ 0.10. Sensitivity
analyses excluding one study at a time were conducted to
clarify whether the results were simply due to one large
study or a study with an extreme result.
Results
We identified 29 prospective studies (32 publications) that
were included in the systematic review of BMI, waist
circumference, hip circumference, waist-to-hip ratio, body
fat mass, body fat percentage, weight, and weight gain and
risk of atrial fibrillation (Supplementary Table 4, Fig. 1)
[18–34, 36–42, 52–59]. Only one study reported on peri-
cardial fat, intrathoracic fat, and abdominal visceral fat and
atrial fibrillation, thus it was not possible to conduct meta-
analyses for these measures [52]. In addition, only one
study reported on BMI and mortality from atrial fibrilla-
tion, thus the study was excluded from the main analysis,
but it was included in a sensitivity analysis [54]. Fourteen
studies were from Europe, eight were from the USA, four
were from Asia, and three were from Australia (Supple-
mentary Table 4).
Body mass index
Twenty-five prospective studies (25 publications)
[18–21, 23–34, 36–40, 42, 55–57] including two nested
case–control studies (were included in the dose–response
analysis of BMI and atrial fibrillation incidence and
included 83,006 incident cases among 2,405,381 partici-
pants. The summary RR for a 5 unit increment in BMI was
1.28 (95% confidence interval: 1.20–1.38, I2 = 97%,
pheterogeneity\ 0.0001; Fig. 2a, Supplementary Table 7 ),
and it was similar when stratified by gender, but the
heterogeneity was lower among men (I2 = 37%) compared
to women (I2 = 98%; Table 1). All but one of the studies
299 reporting on adiposity and atrial fibrillation
6392 excluded based on title or 
abstract
267 articles excluded:
99 patient populations, 
progression, recurrence
40 abstracts 
38 reviews
22 cross-sectional studies
22 comments, editorials, letters
14 not relevant data
10 duplicates
9 case-control studies
7 <3 categories of exposure
3 meta-analyses
1 no risk estimates
1 nonenglish
1 high risk population
32 publications (29 studies) included
6691  records identified in total:
1826 records identified in PubMed
4862 records identified in Embase
3 records from other searches
Fig. 1 Flow-chart of study selection
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found increased risk, but the strength of the association
differed between studies. In sensitivity analyses excluding
the most influential studies, the summary RR ranged from
1.27 (95% CI: 1.18–1.37) when excluding the Danish
Military Conscripts study [28] to 1.30 (95% CI: 1.23–1.38)
when excluding the UK General Practice Research Data-
base Study [20]. There was no indication of publication
bias with Egger’s test, p = 0.31, or with Begg’s test,
p = 0.44, however, by inspection of the funnel plot there
was some evidence of asymmetry with potentially smaller
negative studies missing (Supplementary Fig. 1). There
was evidence of a nonlinear association between BMI and
atrial fibrillation, pnonlinearity\ 0.0001 (Fig. 2b, Supple-
mentary Table 5) with a steeper increase in risk at higher
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B
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Body mass index and atrial fibrillation, linear dose-response analysis, per 5 BMI units
Body mass index and atrial fibrillation, nonlinear dose-response analysis
 Relative Risk
 .5  .75  1  1.5  2  3  5
 Study
 Relative Risk
 (95% CI)
 Berkovitch, 2016   1.46 ( 1.25, 1.71)
 Diouf, 2016   1.03 ( 0.76, 1.40)
 Kang, 2016   1.32 ( 1.11, 1.57)
 Karas, 2016   1.09 ( 1.02, 1.16)
 Aronis, 2015   1.15 ( 1.02, 1.30)
 Kokubo, 2015   1.21 ( 0.95, 1.54)
 Nystrom, 2015   1.30 ( 1.14, 1.49)
 Vermond, 2015   1.45 ( 1.21, 1.74)
 Azarbal, 2014   1.12 ( 1.10, 1.14)
 Frost, 2014   1.33 ( 1.26, 1.38)
 Huxley, 2014   1.38 ( 1.30, 1.46)
 Knuiman, 2014   1.42 ( 1.25, 1.61)
 Reeves, 2014   1.43 ( 1.40, 1.46)
 Sandhu, 2014   1.25 ( 1.18, 1.32)
 Schmidt, 2014   1.66 ( 1.34, 2.05)
 Karasoy, 2013   1.32 ( 1.11, 1.57)
 Nyrnes, 2013   1.47 ( 1.32, 1.64)
 Grundvold, 2012   1.30 ( 1.04, 1.64)
 Korda, 2012   1.16 ( 1.10, 1.23)
 Hodgkinson, 2011   0.94 ( 0.92, 0.97)
 Schnabel, 2010, AGES   1.22 ( 1.05, 1.41)
 Minami, 2009   1.69 ( 0.90, 3.18)
 Rosengren, 2009   1.40 ( 1.28, 1.54)
 Gami, 2007   1.40 ( 1.28, 1.61)
 Wang, 2004   1.22 ( 1.10, 1.35)
 Overall   1.28 ( 1.20, 1.38)
Fig. 2 BMI and atrial fibrillation, linear and nonlinear dose–response analysis
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Table 1 Subgroup analyses of
BMI and atrial fibrillation
BMI
n RR (95% CI) Ia (%) Ph
b Ph
c
All studies 25 1.28 (1.20–1.38) 96.8 \0.0001
Sex
Men 9 1.39 (1.30–1.48) 37.2 0.12 0.05/0.21
Women 7 1.30 (1.14–1.48) 98.1 \0.0001
Men and women 11 1.25 (1.11–1.39) 94.3 \0.0001
Assessment of weight/height
Measured 19 1.27 (1.18–1.37) 95.2 \0.0001 0.66
Self-reported 4 1.28 (1.13–1.45) 94.9 \0.0001
Not available 2 1.41 (1.26–1.58) 0 0.57
Duration of follow-up
\5 years 3 1.28 (1.12–1.47) 78.2 0.01 0.70
5 B 10 years 7 1.37 (1.27–1.47) 38.8 0.13
10 B 15 years 8 1.23 (1.13–1.33) 91.0 \0.0001
15 B 20 years 3 1.33 (1.23–1.44) 72.3 0.03
C20 years 4 1.29 (0.96–1.73) 96.8 \0.0001
Geographic location
Europe 10 1.34 (1.16–1.56) 98.5 \0.0001 0.47
America 8 1.22 (1.14–1.31) 89.8 \0.0001
Australia 3 1.22 (1.04–1.44) 78.1 0.01
Asia 4 1.37 (1.23–1.52) 0 0.53
Number of cases
Cases\ 250 5 1.38 (1.22–1.57) 43.4 0.13 0.10
Cases 250 B 1000 10 1.32 (1.24–1.40) 47.2 0.05
Cases C 1000 10 1.23 (1.11–1.36) 98.7 \0.0001
Study quality
0–3 0 0.92
4–6 3 1.29 (1.08–1.54) 78.3 0.01
7–9 22 1. 28 (1.19–1.38) 97.2 \0.0001
Adjustment for confounders
Age Yes 23 1.27 (1.18–1.37) 97.0 \0.0001 0.24
No 2 1.45 (1.15–1.83) 71.8 0.06
Smoking Yes 14 1.21 (1.11–1.32) 98.1 \0.0001 0.01
No 11 1.40 (1.34–1.47) 0 0.56
Alcohol Yes 12 1.26 (1.11–1.42) 98.2 \0.0001 0.53
No 13 1.30 (1.21–1.40) 86.1 \0.0001
Physical activity Yes 10 1.30 (1.18–1.43) 97.2 \0.0001 0.66
No 15 1.28 (1.16–1.42) 94.3 \0.0001
Adjustment for potential intermediates
Hypertension Yes 11 1.24 (1.13–1.35) 96.3 \0.0001 0.18
No 14 1.33 (1.23–1.43) 88.0 \0.0001
Blood pressure Yes 7 1.26 (1.17–1.35) 32.4 0.18 0.76
No 18 1.29 (1.19–1.40) 97.7 \0.0001
Cholesterol Yes 6 1.28 (1.15–1.43) 93.6 \0.0001 0.99
No 19 1.29 (1.17–1.42) 97.2 \0.0001
Diabetes mellitus Yes 11 1.24 (1.14–1.36) 96.6 \0.0001 0.29
No 14 1.32 (1.22–1.42) 88.2 \0.0001
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BMI values. In a sensitivity analysis, one study of BMI and
atrial fibrillation mortality [54] was included in the anal-
ysis, but the results remained similar, summary RR = 1.29
(95% CI: 1.20–1.38, I2 = 97%, pheterogeneity\ 0.0001) per
5 BMI units.
Waist circumference
Five prospective studies (5 publications) [26, 29–32] were
included in the analysis of waist circumference and risk of
atrial fibrillation incidence and included 6120 cases among
80,752 participants. Three studies were from the USA, one
from Denmark and one from Australia (Supplementary
Table 4). The summary RR for a 10 cm increase in waist
circumference was 1.18 (95% CI: 1.12–1.25, I2 = 73%,
pheterogeneity = 0.005) (Fig. 3a, Supplementary Table 7).
The summary RR ranged from 1.16 (95% CI: 1.10–1.23)
when the Busselton Health Study [29] was excluded to 1.20
(95% CI: 1.15–1.26) when the Cardiovascular Health
Study [32] was excluded. There was no evidence of pub-
lication bias with Egger’s test, p = 0.85 or Begg’s test,
p = 0.99, although the number of studies was limited.
There was no evidence of a nonlinear association between
waist circumference and atrial fibrillation incidence
(pnonlinearity = 0.09; Fig. 3b, Supplementary Table 6).
Waist-to-hip ratio, hip circumference, weight, body fat
mass, body fat percentage, pericardial fat, intrathoracic fat,
and abdominal visceral fat.
Four prospective studies (4 publications) [29, 30, 32, 33]
were included in the analysis of waist-to-hip ratio and risk
of atrial fibrillation (4259 cases and 67,837 participants)
and the summary RR for a 0.1 unit increment in waist-to-
hip ratio was 1.09 (95% CI: 1.02–1.16, I2 = 44%,
pheterogeneity = 0.15) (Fig. 4a, Supplementary Table 7).
Three prospective studies (3 publications) [30, 32, 33]
were included in the analysis of hip circumference and risk
of atrial fibrillation (3916 cases and 63,570 participants)
and the summary RR for a 10 cm increase in hip circum-
ference was 1.32 (95% CI: 1.16–1.51, I2 = 91%,
pheterogeneity\ 0.0001; Fig. 4b, Supplementary Table 7).
Four prospective studies (3 publications) [29, 30, 32, 33]
were included in the analysis of total body fat mass and
atrial fibrillation (5037 cases and 71,098 participants), and
Table 1 continued
BMI
n RR (95% CI) Ia (%) Ph
b Ph
c
Coronary heart disease Yes 13 1.27 (1.16–1.38) 96.3 \0.0001 0.58
No 12 1.30 (1.20–1.41) 90.6 \0.0001
Heart failure Yes 8 1.18 (1.06–1.31) 96.7 \0.0001 0.02
No 17 1.33 (1.26–1.41) 86.8 \0.0001
Left ventricular hypertrophy Yes 2 1.19 (1.10–1.28) 0 0.48 0.39
No 23 1.29 (1.20–1.39) 97.1 \0.0001
n denotes the number of studies
a P for heterogeneity within each subgroup
b P for heterogeneity between subgroups
c P for heterogeneity between men and women (excluding men/women combined)
A
B
Waist circumference and atrial fibrillation, linear dose-response analysis, per 10 cm
.8
1
1.5
2
3
RR
70 80 90 100 110
Waist circumference(cm)
Best fitting fractional polynomial
95% confidence interval
Waist circumference and atrial fibrillation, nonlinear dose-response analysis
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Karas, 2016   1.10 ( 1.05, 1.16)
 Aronis, 2015   1.12 ( 1.03, 1.21)
 Frost, 2014   1.21 ( 1.18, 1.25)
 Huxley, 2014   1.22 ( 1.10, 1.35)
 Knuiman, 2014   1.28 ( 1.16, 1.41)
 Overall   1.18 ( 1.12, 1.25)
Fig. 3 Waist circumference and atrial fibrillation, linear and nonlin-
ear dose–response analysis
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the summary RR for a 5 kg increase in body fat mass was
1.09 (95% CI: 1.02–1.16, I2 = 94%, pheterogeneity\ 0.0001)
(Fig. 4c, Supplementary Table 7).
Three prospective studies (3 publications) [29, 30, 33]
were included in the analysis of body fat percentage and
risk of atrial fibrillation (2952 cases and 57,990 partici-
pants) and the summary RR per 10% increase in fat per-
centage was 1.10 (95% CI: 0.92–1.33, I2 = 90%
pheterogeneity\ 0.0001) (Fig. 4d, Supplementary Table 7).
Ten prospective studies (6 publications)
[30, 32, 33, 53, 58, 59] were included in the analysis of
weight and the risk of atrial fibrillation (7237 cases and
132,006 participants) and the summary RR for a 5 kg
increment in weight was 1.10 (95% CI: 1.08–1.13,
I2 = 74%, pheterogeneity\ 0.0001) (Fig. 5a, Supplementary
Table 7). There was no evidence of publication bias with
Egger’s test, p = 0.52, or Begg’s test, p = 0.59.
Two prospective studies [23, 26] were included in the
analysis of weight gain and the risk of atrial fibrillation (3028
cases and 21,122 participants) and the summaryRRwas 1.08
(95% CI: 0.97–1.19, I2 = 86% pheterogeneity = 0.007)
(Fig. 5b) per 5% increase in weight gain. Only one study
reported on pericardial fat, intrathoracic fat, abdominal vis-
ceral fat and the risk of atrial fibrillation and found hazard
ratios of 1.13 (95% CI: 0.99–1.30), 1.19 (95% CI:
1.01–1.40), 1.09 (95% CI: 0.93–1.28), respectively [52].
Subgroup and sensitivity analyses and study quality
The positive association between BMI, and risk of atrial
fibrillation persisted in almost all subgroup analyses defined
by gender, assessment of weight and height, duration of
follow-up, geographic location, number of cases, study
quality and adjustment for confounding and potential
B
D
Hip circumference and atrial fibrillation, linear dose-response analysis, per 10 cm
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Aronis, 2015   1.04 ( 0.84, 1.28)
 Azarbal, 2014   1.00 ( 0.90, 1.08)
 Frost, 2014   1.26 ( 1.19, 1.34)
 Overall   1.10 ( 0.92, 1.33)
Body fat percentage and atrial fibrillation, linear dose-response analysis, per 10%
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Karas, 2016   1.17 ( 1.10, 1.24)
 Nystrom, 2015   1.47 ( 1.29, 1.66)
 Frost, 2014   1.38 ( 1.31, 1.43)
 Overall   1.32 ( 1.16, 1.51)
A
C
Waist-to-hip ratio and atrial fibrillation, linear dose-response analysis, per 0.1 units
Total body fat mass and atrial fibrillation, linear dose-response analysis, per 5 kg
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Karas, 2016   1.02 ( 0.96, 1.11)
 Nystrom, 2015   1.06 ( 0.86, 1.29)
 Frost, 2014   1.11 ( 1.07, 1.16)
 Knuiman, 2014   1.24 ( 1.02, 1.49)
 Overall   1.09 ( 1.02, 1.16)
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Karas, 2016   1.07 ( 1.04, 1.10)
 Aronis, 2015   1.07 ( 1.00, 1.14)
 Azarbal, 2015   1.04 ( 1.01, 1.07)
 Frost, 2014   1.17 ( 1.14, 1.19)
 Overall   1.09 ( 1.02, 1.16)
Fig. 4 Waist-to-hip ratio, hip circumference, total body fat mass, and body fat percentage and atrial fibrillation
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intermediate factors and there was little evidence of
heterogeneity between any of these subgroups with meta-
regression analyses (Table 1). In further subgroup analyses
of two studies that reported data stratified by ethnicity
[31, 37], the summary RR per 5 BMI units was 1.14 (95%CI:
1.06–1.22) among Caucasians and 1.23 (95%CI: 1.09–1.39)
for African Americans, with no significant heterogeneity
between subgroups, p = 0.39. When the studies of BMI and
atrial fibrillation were stratified by study design, the sum-
mary RR was 1.15 (95% CI: 0.67–1.98, I2 = 69.5%) for the
nested case–control studies and 1.30 (95% CI: 1.23–1.38,
I2 = 94.3%) for the cohort studies. Study quality was high
with a mean (median) score of 7.7 (8) out of 9 points in the
analysis of BMI and atrial fibrillation.
Discussion
This is to our knowledge the first meta-analysis to assess
multiple adiposity measures in relation to risk of atrial
fibrillation. There was a 28% increase in the relative risk
per 5 units increase in BMI, a 18% increase in relative risk
per 10 cm increase in waist circumference, a 9% increase
in the relative risk per 0.1 unit increase in waist-to-hip
ratio, a 32% increase in relative risk per 10 cm increase in
hip circumference, a 9% increase in the relative risk per
5 kg increase in body fat mass, and a 10% increase in the
relative risk per 5 kg increase in body weight, but no sig-
nificant association was observed for body fat percentage
or weight gain, although the number of studies was very
low in these analyses. There was evidence of a nonlinear
association between BMI and atrial fibrillation, with a
slightly steeper association at higher BMI levels, however,
there was evidence of increased risk even within the nor-
mal BMI range (22–24) compared to a BMI of around 20,
although the increased risk was most pronounced in the
obese and severely obese BMI ranges. The association
between waist circumference and atrial fibrillation was
approximately linear. The positive association between
BMI and atrial fibrillation was observed across all geo-
graphic locations and both in Caucasians and African
Americans, suggesting that adiposity is a risk factor for
atrial fibrillation across populations.
The current findings are consistent with a previous meta-
analysis of 5 cohort studies which found a 39 and 87%
increase in the relative risk of atrial fibrillation among
overweight and obese, respectively, compared to normal
weight subjects [35]. However, the current analysis has a
much larger number of studies and cases and participants
(25 studies with 83,006 incident cases among 2,405,381
participants compared to 5 studies with 2114 cases and
78,602 participants) and thus provides a much more robust
estimate of the association, in addition to a more compre-
hensive assessment of different adiposity measures in
relation to risk of atrial fibrillation. Although a recent
randomized trial did not find a statistically significant
reduction in risk of atrial fibrillation among individuals
with type 2 diabetes with a weight loss intervention, the
study may have had too low power to detect a moderate
reduction in risk [60]. The hazard ratio for the highest
quintile of weight loss was 0.70 (95% CI: 0.41–1.18), thus
a moderate reduction in risk cannot be excluded based on
this trial. Another recent study of obese patients undergo-
ing bariatric surgery found a reduced risk of developing
atrial fibrillation with a hazard ratio of 0.71 (95% CI:
0.60–0.83) compared to the control group, providing
additional evidence that adiposity is related to increased
risk of atrial fibrillation [61]. Our findings of an increased
risk of atrial fibrillation with higher hip circumference is
somewhat in contrast to previous studies that have found an
inverse association between hip circumference and car-
diovascular disease [62], however, the inverse associations
were only observed after further adjustment for BMI and
waist circumference while none of the studies in the current
A
B
Weight and atrial fibrillation, linear dose-response analysis, per 5 kg
Weight gain and atrial fibrillation, linear dose-response analysis, per 5%
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Huxley, 2014   1.14 ( 1.06, 1.23)
 Rosengren, 2009   1.03 ( 1.01, 1.04)
 Overall   1.08 ( 0.97, 1.19)
 Relative Risk
 .5  .75  1  1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Karas, 2016   1.09 ( 1.02, 1.16)
 Nystrom, 2015   1.15 ( 1.10, 1.19)
 Frost, 2014   1.09 ( 1.08, 1.11)
 Alonso, 2013, AGES   1.05 ( 1.01, 1.09)
 Alonso, 2013, ARIC   1.12 ( 1.08, 1.15)
 Alonso, 2013, CHS   1.06 ( 1.03, 1.10)
 Alonso, 2013, FHSOC   1.07 ( 1.01, 1.13)
 Alonso, 2013, RS   1.16 ( 1.09, 1.23)
 Conen, 2013   1.07 ( 1.00, 1.14)
 Wilhelmsen, 2001   1.23 ( 1.16, 1.31)
 Overall   1.10 ( 1.08, 1.13)
Fig. 5 Weight and weight change and atrial fibrillation
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meta-analysis made further adjustments for BMI and waist
circumference. Further studies are therefore needed to
clarify whether hip circumference, waist circumference and
BMI are independently associated with atrial fibrillation.
Our meta-analysis has some limitations that need to be
mentioned. Confounding by other risk factors may have
influenced the results. However, the association between
BMI and atrial fibrillation persisted in subgroup analyses
when studies were stratified by whether they adjusted for
confounding factors such as age, smoking, alcohol, and
physical activity. In addition, the association persisted
among studies that adjusted for potential intermediates
including hypertension, blood pressure, serum cholesterol,
diabetes, coronary heart disease, heart failure, and left
ventricular hypertrophy. There was some evidence of
heterogeneity between the subgroups of studies that
adjusted for heart failure, with weaker, but still significant
associations among studies with such adjustment. This
could indicate that part of the association between adi-
posity and atrial fibrillation may be mediated by heart
failure. This is consistent with our previous finding of an
increased risk of heart failure related to both general and
abdominal adiposity [7] and with the increased risk of atrial
fibrillation among patients with heart failure [53]. Although
the heterogeneity between studies was high, this appeared
to be largely due to different effect sizes between studies,
rather than differences in the direction of the association, as
all but one study found a positive association. Exclusion of
the study which showed an inverse association in the linear
dose–response analysis did not substantially reduce the
heterogeneity.
Measurements of weight, height, waist and hip circum-
ferences may have been affected by measurement errors,
however, the association for BMI was similar among
studies that used measured weight and height compared to
those that used self-reported weight and height. Validation
studies have reported high correlations between self-re-
ported and measured anthropometric measures [63–66].
BMI is an imperfect measure of body fatness as it does not
distinguish between body fat and muscle mass. However,
studies have shown high correlations between BMI and
waist measures and body fat as measured by dual-energy
X-ray absorptiometry (DXA) [67, 68]. Importantly, the
association between adiposity and atrial fibrillation was in
the direction of increased risk for all adiposity measures
analysed, and the association with body fat mass (measured
by DXA) did not appear to be stronger than that for BMI or
waist circumference, supporting the use of these measures
for the measurement of adiposity and for prediction of
atrial fibrillation. Although publication bias or small study
bias can affect the findings of meta-analyses of published
literature, we found no evidence of such bias with Egger’s
or Begg’s test. However, power was low for these tests in
the analyses apart from BMI and weight because the
number of studies was low.
Several potential mechanisms could explain an associ-
ation between body fatness and risk of atrial fibrillation.
Adiposity is associated with increased risk of hypertension
[2], insulin resistance [69], diabetes [70], obstructive sleep
apnea [71], coronary heart disease [72], and heart failure
[7], which are established risk factors for atrial fibrillation
[53, 73, 74]. Adiposity is associated with increased risk of
left ventricular hypertrophy [75–77] and left atrial size
[78, 79], and the latter may be due to hypertension, volume
overload, left ventricular diastolic abnormalities, auto-
nomic dysfunction and enhanced neurohormonal activation
[80, 81]. In an experimental animal study weight gain
resulted in atrial remodeling and increased atrial volumes,
left atrial and systemic pressures, ventricular mass, peri-
cardial fat volumes, increased atrial interstitial fibrosis,
inflammation, myocardial lipid accumulation, and con-
duction abnormalities with slowing of atrial conduction
and increased conduction heterogeneity [82]. Adiposity is
related to low-grade inflammation [83, 84] which is
strongly associated with atrial fibrillation [85]. Overweight
and obesity is also related to greater epicardial fat thickness
[86–88] which has been associated with alterations in atrial
electrophysiology [89] and risk of atrial fibrillation
[90, 91]. The findings of a recent Mendelian Randomisa-
tion study of genetic obesity and atrial fibrillation is con-
sistent with a causal interpretation of the positive
association found in the current meta-analysis between
adiposity and atrial fibrillation [92].
Our meta-analysis has several strengths including the
prospective design of the included studies which avoids
recall bias and reduces the possibility for selection bias, the
large number of cohort studies with[83,000 cases
and[2.4 million participants in the BMI analysis which
provided statistical power to detect moderate associations,
the detailed dose–response analyses which clarified the
shape of the dose–response relationship, the observation of
a similar association between BMI and atrial fibrillation in
different geographic regions, and robustness of the findings
in multiple subgroup analyses as well as the high study
quality of the included studies.
The findings have important clinical implications for the
prevention of atrial fibrillation as a previous meta-analysis
only analysed BMI, but not other fat measures in relation to
the risk of atrial fibrillation [35], and have not assessed the
dose–response relationship between adiposity and atrial
fibrillation in as much detail as the current analysis. In
addition, we found in subgroup analyses that higher BMI
was associated with increased risk of atrial fibrillation in
studies from Europe, North America, Australia and Asia, as
well as in Caucasian and African American participants
suggesting that avoidance of excess weight is important
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across populations. The current analysis suggests that both
general and abdominal adiposity measures as well as
increased hip circumference and total body fat mass is
related to increased risk of atrial fibrillation and that being
relatively slim as assessed by BMI, waist circumference
and other adiposity measures may confer the lowest risk of
atrial fibrillation. However, to what degree different fat
measures independently of each other predict atrial fibril-
lation risk is not clear from the current data as few studies
reported mutually adjusted results, but this requires further
study. Because of the moderate number of studies in the
analyses of other adiposity measures than BMI and weight
further studies are needed of these measures. These find-
ings have important public health implications because of
the increasing prevalence of overweight and obesity
worldwide [1] and because of the consistency of the results
across populations. Thus if current trends continue una-
bated it might contribute to an increased incidence of atrial
fibrillation and associated complications globally [16].
In conclusion, our findings confirm that overweight,
obesity, abdominal fatness and high body fat mass increase
the risk of atrial fibrillation.
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Supplementary Table 4: Prospective studies of adiposity and atrial fibrillation risk  
Author, 
publication 
year, country/ 
region 
Study name Recruitment 
and follow-up 
period 
Study size, gender, 
age, number of 
cases 
Assessment 
of weight 
and height 
Exposure by 
subgroup 
Description of 
quantiles of categories 
RR (95% CI) Adjustment for confounders 
Wilhelmsen L 
et al, 2001, 
Sweden 
The Multifactor 
Primary 
Prevention 
Study 
1970-1973 – 
1996, 25.2 
years follow-up 
7495 men, age 47-55 
years: 754 AF cases 
 
Measured  Body weight 
 
 
≤72.9 kg 
73.0-83.9 
≥84.0 
 
1.00 
1.58 (1.28-1.93) 
2.19 (1.78-2.69) 
 
Age  
Wang TJ et al, 
2004, USA 
Framingham 
Heart Study 
1979-1982/1979-
1983 – 1999, 
13.7 years 
follow-up 
 
5282 men and 
women, age 35-90 
years: 526 AF cases 
 
Measured  BMI, men 
 
 
 
BMI, women 
 
 
 
BMI, men 
 
 
 
BMI, women 
<25.0 
25.0-<30.0 
≥30.0 
Per 1 unit 
<25.0 
25.0-<30.0 
≥30.0 
Per 1 unit 
<25.0 
25.0-<30.0 
≥30.0 
Per 1 unit 
<25.0 
25.0-<30.0 
≥30.0 
Per 1 unit 
1.00 
1.09 (0.82-1.43) 
1.49 (1.06-2.09) 
1.04 (1.01-1.07) 
1.00 
1.20 (0.90-1.62) 
1.59 (1.13-2.22) 
1.04 (1.01-1.07) 
1.00 
1.10 (0.84-1.46) 
1.52 (1.09-2.13) 
1.04 (1.01-1.07) 
1.00 
1.13 (0.84-1.52) 
1.46 (1.03-2.07) 
1.04 (1.01-1.07) 
Age, SBP, use of antihypertensive 
therapy, DM, ECG –LVH, prior MI 
or CHF, cigarette smoking, 
significant heart murmur 
 
 
 
 
+adjusted for interim MI/CHF 
Frost L et al, 
2005, 
Denmark 
Danish Diet, 
Cancer, and 
Health Study 
1993-2001, 5.7 
years follow-up 
 
22482 men and 
25107 women, age 
50-64 years: 553 AF 
cases 
 
Measured  BMI, men 
 
 
 
BMI, women 
18.5-25.0 
25.0-30.0 
≥30.0 
Per 1 unit 
18.5-25.0 
25.0-30.0 
≥30.0 
Per 1 unit 
1.00 
1.75 (1.35-2.27) 
2.35 (1.70-3.25) 
1.08 (1.05-1.11) 
1.00 
1.39 (0.99-1.94) 
1.99 (1.31-3.02) 
1.06 (1.03-1.09) 
Age, height, length of education, 
smoking status, alcohol, total 
cholesterol, hypertension treatment, 
SBP 
Murphy NF et 
al, 2006, 
United 
Kingdom 
Renfrew-Paisley 
Study 
1972-1976 - 
NA, 20 years 
follow-up 
 
15402 men and 
women, age 45-64 
years: 5 AF deaths 
 
Measured  BMI, all 
BMI, men 
BMI, women 
BMI, all 
Per unit 
Per unit 
Per unit 
18.5-24.9 
1.08 (0.94-1.25) 
1.04 (0.52-2.06) 
1.07 (0.92-1.25) 
1.00 
Age, sex (all), adjusted FEV1, 
cigarettes per day, social class 
  
 
 
BMI, men 
 
 
 
BMI, women 
25.0-29.9 
≥30.0 
Per unit 
18.5-24.9 
25.0-29.9 
≥30.0 
Per unit 
18.5-24.9 
25.0-29.9 
≥30.0 
Per unit 
1.12 (0.80-1.57) 
1.64 (1.07-2.51) 
1.05 (1.01-1.08) 
1.00 
1.19 (0.74-1.92) 
0.96 (0.42-2.20) 
0.99 (0.93-1.06) 
1.00 
1.02 (0.63-1.64) 
2.02 (1.20-3.39) 
1.06 (1.02-1.11) 
Gami AS et al, 
2007, USA 
Olmsted County 
Study 
1987-2003, 4.7 
years follow-up 
 
3542 men and 
women, mean age 49 
years: 133 AF cases 
Unclear  BMI Per 1 unit 1.07 (1.05-1.10) Age, sex, CAD, lowest nocturnal 
oxygen saturation 
Minami M et 
al, 2009, 
Japan 
Ishikawa 
Prefecture 
1998-2006, NA 69 AF cases (men) 
138 controls (nested 
case-control study) 
 
Unclear BMI Per 1 unit 1.11 (0.98-1.26) Age, time period, SBP, TCH, 
gamma-glutamyltranspeptidase, 
uric acid, fasting plasma glucose, 
hemoglobin, cardiomegaly, 
Brinkman index, alcohol 
Rosengren A 
et al, 2009, 
Sweden 
The Multifactor 
Primary 
Prevention 
Study 
1970-1973 - 
2004, 34.3 years 
follow-up 
 
6903 men, age 47-56 
years: 1253 AF 
hospital discharge 
diagnosis cases 
 
Measured 
(current) 
Self-reported 
(weight at age 
20 years) 
BMI at age 20 
 
 
 
 
Midlife BMI 
 
 
 
 
 
 
Body surface area 
 
 
 
Weight change from 
age 20 to midlife 
<21 
21-22.2 
22.3-23.7 
>23.7 
Per 1 unit 
<20.00 
20.00-22.49 
22.50-24.99 
25.00-27.49 
27.50-29.99 
≥30.00 
Per 1 unit 
<1.75 m
2
 
1.75-1.83 
1.83-1.91 
>1.91 
Loss of more than 4% 
-4 to +4% 
+5-15% 
+16-35% 
1.00 
1.02 (0.87-1.20) 
1.06 (0.91-1.25) 
1.28 (1.10-1.50) 
1.05 (1.02-1.08) 
1.11 (0.67-1.78) 
1.00 
1.15 (0.94-1.41) 
1.32 (1.10-1.66) 
1.50 (1.21-1.88) 
1.56 (1.20-2.02) 
1.04 (1.02-1.06) 
1.00 
1.39 (1.16-1.66) 
1.52 (1.28-1.81) 
1.95 (1.65-2.31) 
1.11 (0.84-1.47) 
1.00 
1.08 (0.90-1.30) 
1.22 (1.02-1.47) 
Age 
 
 
 
 
Age, intercurrent heart failure, 
intercurrent MI, SBP, treatment for 
hypertension, smoking, diabetes, 
alcohol, occupational class 
+>35% 1.31 (1.02-1.68) 
Schnabel RB 
et al, 2010, 
Iceland 
Age, Gene/ 
Environment 
Susceptibility-
Reykjavik 
Study 
2002-2006 – 
2008, 5 years 
follow-up 
 
4238 men and 
women, age 45-95 
years: 226 AF 
cases 
 
Measured  BMI Per 5 units 1.22 (1.05-1.41) Age, sex, SBP, hypertension 
treatment, PR interval, prevalent 
heart failure 
Schnabel RB 
et al, 2010, 
USA 
Cardiovascular 
Health Study 
1989-1990/ 
1992-1993 – 
2005, 5 years 
follow-up 
5410 men and 
women, age 45-95 
years: 958 AF 
cases 
Measured  BMI, whites 
BMI, African 
Americans 
Per 5 units 
Per 5 units 
1.14 (1.05-1.23) 
1.29 (1.10-1.51) 
Age, sex, SBP, hypertension 
treatment, PR interval, valvular 
heart disease (whites only), 
prevalent heart failure 
Hodgkinson 
JA et al, 2011, 
United 
Kingdom 
UK General 
Practice 
Research 
Database 
1987-2007, NA 
 
44348 AF cases 
161104 controls 
(nested case-
control study) 
 
Measured  BMI 10-19 
20-24 
25-29 
≥30 
1.14 (1.09-1.19) 
1.00 
1.02 (0.91-1.14) 
1.29 (1.15-1.45) 
Age, sex, practice, calendar time, 
COPD, cerebrovascular accident, 
diabetes, heart failure, 
hyperthyroidism, IHD, 
hypertension, bisphosphonates, oral 
glucocorticoids, statins, xanthine 
derivate, beta-2 agonists, drugs 
affecting the renin-angiotensin-
aldosterone system, alcohol, 
smoking 
Grundvold I et 
al, 2012, 
Norway 
Oslo 
Cardiovascular 
Health Survey 
1972-1975 – 
2008, 30 years 
follow-up 
2014 men, age 40-59 
years: 270 AF cases 
 
Measured  BMI Per 2.8 units 1.16 (1.02-1.32) Age, SBP, DBP, physical fitness, 
exercise maximal heart rated, pulse 
pressure, exercise maximal SBP 
Korda RJ et 
al, 2012, 
Australia 
The 45 and Up 
Study 
2006-2009, 2.3 
years follow-up 
246361 men and 
women, age ≥45 
years: 1880 AF 
cases 
 
Self-reported BMI, age 45-64 
years 
 
BMI, age 65-79 
years 
 
BMI, age ≥80 years 
18.5-<25.0 
25.0-<30.0 
≥30.0 
18.5-<25.0 
25.0-<30.0 
≥30.0 
18.5-<25.0 
25.0-<30.0 
≥30.0 
1.00 
1.37 (1.09-1.72) 
1.84 (1.45-2.33) 
1.00 
1.07 (0.91-1.26) 
1.33 (1.11-1.60) 
1.00 
1.04 (0.87-1.25) 
1.15 (0.88-1.50) 
Age, sex, region of residence, 
household income, smoking, 
alcohol, private health insurance 
status,  
Alonso A et 
al, 2013, USA 
Framingham 
Heart Study 
Offspring 
cohort 
1995-1998 - 
2005, NA years 
of follow-up 
2838 men and 
women, mean age 
60 years: 143 cases  
Measured Weight Per 15 kg 
 
1.22 (1.03-1.44) Age, sex 
Alonso A et 
al, 2013, USA 
Cardiovascular 
Health Study 
1989-1990, 
1992-1993 - 
2000, NA years 
5043 men and 
women, age ≥65 
years: 624 cases 
Measured  Weight, whites 
Weight, blacks 
Per 15 kg 
Per 15 kg 
 
1.18 (1.07-1.31) 
1.31 (1.04-1.65) 
Age, sex 
of follow-up 
Alonso A et 
al, 2013, USA 
Atherosclerosis 
Risk in 
Communities 
Cohort 
1996-1998, -
2005, NA years 
of follow-up 
10675 men and 
women, age 45-64 
years: 419 cases 
Measured  Weight, whites 
Weight, blacks 
Per 15 kg 
Per 15 kg 
 
1.39 (1.26-1.53) 
1.44 (1.08-1.91) 
Age, sex 
Alonso A et 
al, 2013, 
Island 
Age, Gene/ 
Environment 
Susceptibility 
Reykjavik 
Study 
2002-2006 - 
2011, NA years 
of follow-up 
4469 men and 
women, mean age 
76 years: 408 cases 
Measured  Weight Per 15 kg 
 
1.17 (1.04-1.31) Age, sex 
Alonso A et 
al, 2013, 
Netherlands 
Rotterdam 
Study 
1997-2005, NA 
years of follow-
up 
3203 men and 
women, age ≥55 
years: 177 cases 
Measured  Weight Per 15 kg 
 
1.55 (1.28-1.87) Age, sex 
Conen D et al, 
2013, USA 
Women's Health 
Study 
NA-2011, 16.4 
years follow-up 
 
34713 women, age 
≥45 years: 796 AF 
cases 
Self-reported Body weight 
 
Per 10 kg 
 
1.07 (0.998-1.14) 
 
Age, hypertension, diabetes, race, 
education, alcohol, smoking, 
exercise, height 
Karasoy D et 
al, 2013, 
Denmark 
Danish Pregnant 
Women 
2004-2009 - 
2010, 4.6 years 
follow-up 
271203 women, 
mean age 30.6 years: 
110 AF 
hospitalizations 
 
Measured  BMI <18.5 
18.5-25 
25-29.9 
30-35 
>35 
1.65 (0.88-3.35) 
1.00 
1.13 (0.68-1.88) 
2.04 (1.13-3.69) 
3.50 (1.86-6.58) 
Age, hyperthyroidism, previous use 
of beta-blockers 
Nyrnes A et 
al, 2013, 
Norway 
The Tromsø 
study 
1994-1995 - 
2007, 11 years 
follow-up 
 
22815 men and 
women, age 25-96 
years: 461/361 AF 
cases 
 
Measured  BMI, all AF, men 
BMI, lone AF, men 
BMI, all AF, women 
BMI, lone AF, 
women 
Per 3.2 units 
Per 3.2 units 
Per 4.1 units 
Per 4.1 units 
1.16 (1.06-1.27) 
1.47 (1.32-1.63) 
1.47 (0.90-2.40) 
2.13 (1.47-3.09) 
Age, height, total cholesterol, HDL-
cholesterol, hypertension, 
palpitations, diabetes (all AF only), 
CHD (all AF only) 
Azarbal F et 
al, 2014, USA 
Women’s 
Health Initiative 
1994-1998 – 
2011, 11.5 years 
follow-up 
 
81317 women, age 
50-79 years: 9792 
AF cases 
 
Measured BMI Per 5 units 1.12 (1.10-1.14) Age, race/ethnicity, education, 
hypertension, diabetes, 
hyperlipidemia, CAD, heart failure, 
PAD, current smoking, physical 
activity 
Reeves GK et 
al, 2014, 
United 
Kingdom 
Million 
Women's Study 
1996-2001 – 
2008, 9.2 years 
follow-up 
1251619 women, 
age 50-64 years: 
11078 AF 
hospitalizations  
 
Self-reported BMI <22.5 
22.5-24.9 
25.0-29.9 
30.0-34.9 
≥35.0 
Per 5 units 
0.95 (0.91-1.00) 
1.00 (0.96-1.04) 
1.24 (1.20-1.28) 
1.75 (1.67-1.82) 
2.90 (2.74-3.07) 
1.43 (1.40-1.46) 
Age, geographical region, SES, age 
at 1
st
 birth, parity, smoking status, 
alcohol intake, physical activity, 
time since menopause, HRT use 
Huxley RR et Atherosclerosis 1987-2009, 14219 men and Measured  BMI 18.5-24.9 1.00 Age, sex, race, study site, education, 
al, 2014, USA Risk in 
Communities 
Study 
~18.2 years 
follow-up 
women, age 45-64 
years: 1775 AF 
cases  
 
 
 
 
Waist circumference 
 
 
 
Weight change, men 
 
 
 
 
Weight change, 
women 
25.0-29.9 
≥30.0 
≤92/≤84 cm 
93-98/85-94 
99-105/95-105 
≥106/≥106 
>5% loss 
0-5% loss 
0 to 4.9% gain 
5-9.9 gain 
≥10% gain 
>5% loss 
0-5% loss 
0 to 4.9% gain 
5-9.9 gain 
≥10% gain 
1.20 (1.06-1.36) 
1.95 (1.72-2.21) 
1.00 
1.18 (1.01-1.37) 
1.52 (1.31-1.76) 
2.13 (1.85-2.46) 
1.52 (1.16-1.99) 
1.01 (0.79-1.31) 
1.00 
1.33 (1.04-1.70) 
1.61 (1.24-2.11) 
1.45 (1.08-1.93) 
1.24 (0.93-1.64) 
1.00 
1.24 (0.94-1.62) 
1.19 (0.90-1.55) 
income, prior CVD, cigarette 
smoking, height, physical activity, 
alcohol 
Sandhu RK et 
al, 2014, USA 
Women’s 
Health Study 
1993 – 2004, 
16.4 years 
follow-up 
 
34720 women, age 
≥45 years: 690 
paroxysmal AF 
cases 
349 nonparoxysmal 
AF cases 
 
Self-reported BMI, paroxysmal AF 
 
 
 
BMI, nonparoxysmal 
AF 
 
 
BMI, paroxysmal AF 
 
 
 
BMI, nonparoxysmal 
AF 
 
 
<25 
25-<30 
≥30 
Per 1 unit 
<25 
25-<30 
≥30 
Per 1 unit  
<25 
25-<30 
≥30 
Per 1 unit 
<25 
25-<30 
≥30 
Per 1 unit 
1.00 
1.30 (1.08-1.55) 
1.49 (1.22-1.83) 
1.03 (1.02-1.05) 
1.00 
1.51 (1.15-1.97) 
2.56 (1.93-3.40) 
1.07 (1.05-1.09) 
1.00 
1.30 (1.08-1.55) 
1.50 (1.22-1.84) 
1.03 (1.02-1.05) 
1.00 
1.51 (1.15-1.97) 
2.57 (1.93-3.40) 
1.07 (1.05-1.09) 
Age, aspirin, vitamin E, beta-
carotene, hypertension, diabetes, 
cholesterol, alcohol, smoking, 
exercise,  
 
 
 
 
+ interim MI, stroke, 
revascularization, heart failure 
Frost L et al, 
2014, 
Denmark 
Danish Diet, 
Cancer and 
Health Study 
1993-1997 -  
13.5 years 
follow-up 
 
55273 men and 
women, age 50-64 
years: 1669/912 AF 
cases 
 
Measured  Weight 
Weight, adj. height 
BMI 
Waist circumference 
Hip circumference 
WHR 
Fat mass 
Per 14.1 kg 
Per 14.1 kg 
Per 4.1 units 
Per 12.7 cm 
Per 7.9 cm 
Per 0.10 units 
Per 8.3 kg 
1.36 (1.31-1.40) 
1.29 (1.24-1.34) 
1.26 (1.21-1.30) 
1.28 (1.23-1.33) 
1.29 (1.24-1.33) 
1.11 (1.07-1.16) 
1.29 (1.24-1.33) 
Age, smoking status, fruit and 
vegetables, alcohol, physical 
activity, total energy, education, 
hypertension, diabetes, 
hypercholesterolemia, IHD, CHF, 
vascular heart disease 
Fat mass, adj. LBM 
Fat% 
Lean body mass 
LBM, adj. height 
LBM, adj. fat mass 
Per 8.3 kg 
Per 7.4% 
Per 9.7 kg 
Per 9.7 kg 
Per 9.7 kg 
1.03 (0.99-1.09) 
1.19 (1.14-1.24) 
1.40 (1.35-1.45) 
1.38 (1.32-1.45) 
1.37 (1.30-1.44) 
Schmidt M et 
al, 2014, 
Denmark 
Danish Military 
Conscripts 
1977-2012, 26 
years follow-up 
12850 men, median 
age 19 years: 227 
AF cases 
 
Measured  BMI <18.5 
18.5-24.9 
25.0-29.9 
≥30.0 
0.99 (0.52-1.87) 
1.00 
2.08 (1.48-2.92) 
2.87 (1.46-5.62) 
Years of education, height 
Knuiman M et 
al, 2014, 
Australia 
The Busselton 
Health Study 
1994-1995 - 
2010, 15 years 
follow-up 
4267 men and 
women, age 25-84 
years: 343 AF cases 
Measured  BMI 
WC 
WHR 
Per 4.2 units 
Per 12.7 cm 
Per 0.09 units 
1.34 (1.21-1.49) 
1.37 (1.21-1.55) 
1.21 (1.02-1.43) 
Age, sex, height 
Aronis KN et 
al, 2015, USA 
Health, Aging, 
and Body 
Composition 
Study 
 
1997-1998 – 
2008, 10 years 
follow-up 
2717 men and 
women, mean age 74 
years: 371 AF cases 
 
Measured  BMI, all 
Abdominal 
circumference 
SAT 
VAT 
SAT+VAT 
Total fat mass 
Total fat percent 
BMI, whites 
Abdominal 
circumference 
SAT 
VAT 
SAT+VAT 
Total fat mass 
Total fat percent 
BMI, blacks 
Abdominal 
circumference 
SAT 
VAT 
SAT+VAT 
Total fat mass 
Total fat percent 
Per 4.7 units 
Per 13 cm 
 
Per 120 cm
2
 
Per 67 cm
2 
Per 1 SD 
Per 9 kg 
Per 8% 
Per 4.7 units 
Per 13 cm 
 
Per 120 cm
2
 
Per 67 cm
2 
Per 1 SD 
Per 9 kg 
Per 8% 
Per 4.7 units 
Per 13 cm 
 
Per 120 cm
2
 
Per 67 cm
2 
Per 1 SD 
Per 9 kg 
Per 8% 
1.14 (1.02-1.28) 
1.16 (1.04-1.28) 
 
1.11 (0.97-1.27) 
1.07 (0.96-1.19) 
1.10 (0.98-1.25) 
1.13 (1.002-1.27) 
1.03 (0.87-1.22) 
1.11 (0.96-1.30) 
1.13 (0.94-1.36) 
 
1.16 (0.98-1.38) 
1.04 (0.92-1.19) 
1.12 (0.96-1.30) 
1.16 (0.99-1.34) 
1.06 (0.85-1.31) 
1.13 (0.94-1.36) 
1.27 (1.06-1.52) 
 
0.98 (0.78-1.22) 
1.16 (0.93-1.45) 
1.04 (0.84-1.29) 
1.04 (0.86-1.27) 
0.92 (0.69-1.23) 
Age, sex, race, site, smoking, 
adiposity measure, systolic and 
diastolic blood pressure, treatment 
of hypertension, total to HDL 
cholesterol ratio, heart rate, ECG 
left ventricular hypertrophy, PR 
interval, prevalent heart failure, 
coronary artery disease, diabetes 
Azarbal F et 
al, 2015, USA 
Women’s 
Health Initiative 
1994-1998 – 
2011,11.6 years 
follow-up 
8832 women, mean 
age 63.3 years: 1035 
AF cases 
Measured  BMI 
Total body lean mass 
Central lean mass 
Per 5 units 
Per 5 units 
Per 5 units 
1.07 (1.01-1.13) 
1.21 (1.14-1.29) 
1.49 (1.31-1.69) 
Age, ethnicity, education, 
hypertension, diabetes, 
hyperlipidemia, coronary artery 
  Peripheral lean mass 
Total LBMI 
Central LBMI 
Peripheral LBMI 
Total body fat mass 
Central fat mass 
Peripheral fat mass 
Total body fat% 
Central fat% of 
central mass 
Central fat% of total 
fat mass 
Per 5 units 
Per 5 units 
Per 5 units 
Per 5 units 
Per 5 kg 
Per 5 kg 
Per 5 kg 
Per 5 % 
Per 5 % 
 
Per 5 % 
1.37 (1.21-1.56) 
1.39 (1.15-1.67) 
2.03 (1.41-2.91) 
1.74 (1.22-2.50) 
1.04 (1.01-1.07) 
1.05 (1.00-1.11) 
1.10 (1.04-1.16) 
1.00 (0.95-1.04) 
0.98 (0.94-1.03) 
 
0.95 (0.90-0.99) 
 
disease, heart failure, peripheral 
artery disease, smoking, dietary 
modification, and hormone 
intervention 
Vermond RA 
et al, 2015, 
Netherlands 
Prevention of 
Renal and 
Vascular End-
Stage Disease 
NA-2008, 9.7 
years follow-up 
 
8265 men and 
women, age 28-75 
years: 265 AF cases 
 
Measured  BMI Per 5 units 1.45 (1.21-1.74) Age, sex 
Nyström PK 
et al, 2015, 
Sweden 
Stockholm 
County Study 
 
1997-1999 – 
2012, 13.6 
years follow-up 
1924 men and 2097 
women, age 60 
years: 285 AF cases 
 
Measured  Weight 
Waist circumference 
Hip circumference 
SAD 
BMI 
WHR 
BMI, no MetS 
BMI, MetS 
BMI, no MetS 
BMI, MetS 
BMI, no MetS 
BMI, MetS 
WC, no MetS 
WC, MetS 
WC, no MetS 
WC, MetS 
WC, no MetS 
WC, MetS 
Per 14.2 kg 
Per 12.4 cm 
Per 8.4 cm 
Per 2.9 cm 
Per 4.2 kg/m
2
 
Per 0.087 units 
18.5-24.9 
18.5-24.9 
25.0-29.9 
25.0-29.9 
≥30.0 
≥30.0 
<94/<80 cm 
<94/<80 cm 
94-101.9/80-87.9 
94-101.9/80-87.9 
≥102/≥88  
≥102/≥88 
1.47 (1.31-1.65) 
1.35 (1.19-1.54) 
1.38 (1.24-1.53) 
1.28 (1.14-1.44) 
1.25 (1.12-1.40) 
1.05 (0.88-1.25) 
1.00 
1.17 (0.51-2.70) 
1.01 (0.73-1.40) 
1.67 (1.16-2.41) 
1.75 (1.11-2.74) 
1.92 (1.34-2.74) 
1.00 
1.45 (0.88-2.38) 
1.19 (0.80-1.78) 
1.33 (0.86-2.04) 
1.37 (0.91-2.07) 
2.03 (1.44-2.87) 
Hypertension, elevated fasting 
glucose, sex, smoking, alcohol, 
history of MI, regular moderate-
intensity physical activity, 
Swedish-born 
Kokubo Y et 
al, 2015, 
Japan 
The Suita Study 
 
1989-
1996/1996-
1998/1992-
2006 – 2013, 
12.8 years 
6906 men and 
women, age 30-84 
years: 253 AF cases 
 
Measured BMI <18.5 
18.5-<25.0 
≥25.0 
1.02 (0.60-1.72) 
1.00 
1.35 (1.01-1.80) 
Age, sex, blood pressure, smoking, 
drinking, hyperlipidemia, diabetes 
mellitus, impaired fasting glucose 
follow-up 
Berkovitch A 
et al, 2016, 
Israel 
The Institute for 
Medical 
Screening of the 
Chaim Sheba 
Medical Center 
2000 - NA, 6.4 
years follow-up 
18290 men and 
women, mean age 
48.9 years: 288 AF 
cases 
Measured  BMI 18.5-24.9 
25.0-29.9 
≥30.0 
1.00 
1.49 (1.11-2.00) 
2.34 (1.64-3.34) 
Age, sex, IHD, diabetes mellitus, 
hypertension, LDL cholesterol, 
HDL cholesterol, physical activity 
Diouf I et al, 
2016, 
Australia 
Australian 
Diabetes, 
Obesity and 
Lifestyle study 
cohort 
1999/2000 - 
2004/2005, 5 
years follow-up 
5389 men and 
women, age ≥35 
years:  53 AF cases 
Measured BMI 18.5-24.9 
25.0-29.9 
≥30.0 
1.0 
1.0 (0.7-1.5) 
1.4 (0.5-4.2) 
Age, sex, smoking status, usual 
number of alcoholic drinks, 
physical activity, level of education 
Karas MG et 
al, 2016, USA 
Cardiovascular 
Health Study 
 
1989-2008, 13 
years follow-up 
4276 men and 
women, age ≥65 
years: 1050 AF 
cases 
Measured  BMI 
Weight 
Waist circumference 
Hip circumference 
WHR 
Fat mass 
Fat-free mass 
Per 4.7 units 
Per 14.6 kg 
Per 13.2 cm 
Per 10.0 cm 
Per 0.09 units 
Per 10.8 kg 
Per 9.2 kg 
1.08 (1.02-1.15) 
1.21 (1.13-1.29) 
1.14 (1.07-1.22) 
1.17 (1.10-1.24) 
1.02 (0.96-1.10) 
1.16 (1.09-1.24) 
1.26 (1.13-1.40) 
Age, sex, race, smoking status 
Kang SH et al, 
2016, Korea 
Korea National 
Health 
Insurance 
Corporation 
Study 
2003-2004 - 
NA, 9.0 years 
follow-up 
132063 men and 
women, age ≥40 
years: 3237 AF 
cases 
Measured  BMI, all 
 
 
 
 
BMI, men 
 
 
 
 
BMI, women 
 
<18.5 
18.5-22.9 
23.0-24.9 
25.0-29.9 
≥30.0 
<18.5 
18.5-22.9 
23.0-24.9 
25.0-29.9 
≥30.0 
<18.5 
18.5-22.9 
23.0-24.9 
25.0-29.9 
≥30.0 
1.23 (1.00-1.52) 
1.00 
1.15 (1.05-1.27) 
1.26 (1.16-1.38) 
2.20 (1.87-2.59) 
1.17 (0.90-1.53) 
1.00 
1.09 (0.97-1.23) 
1.22 (1.09-1.37) 
2.17 (1.71-2.75) 
1.32 (0.95-1.84) 
1.00 
1.24 (1.07-1.44) 
1.30 (1.13-1.50) 
2.22 (1.77-2.79) 
Age, sex, alcohol, exercise 
frequency, hypertension, diabetes, 
ischemic heart disease, congestive 
heart failure, chronic kidney 
disease, chronic lung disease, 
malignancy, thyroid disease, 
fasting glucose, urine protein 
Lee JJ et al, 
2016, USA 
Framingham 
Heart Study 
Offspring and 
Third-
Generation 
1998-2001 and 
2002-2005 - 
NA, 9.7 years 
follow-up 
2135 men and 
women, age : 162 
AF cases 
Measured  Pericardial fat 
Intrathoracic fat 
Abdominal visceral 
fat 
Per 46 cm
3
 
Per 63 cm
3
 
Per 1061 cm
3
 
 
1.13 (0.99-1.30) 
1.19 (1.01-1.40) 
1.09 (0.93-1.28) 
Age, sex, SBP, DBP, current 
smoking, antihypertensive 
medication use, diabetes mellitus, 
history of heart failure, history of 
myocardial infarction 
Cohorts 
 
AF=atrial fibrillation, BMI=body mass index, CHD=coronary heart disease, CHF=congestive heart failure, COPD=chronic obstructive pulmonary disease, 
CVD=cardiovascular disease, DBP=diastolic blood pressure, ECG=electrocardiogram, FEV1=forced expiratory volume in 1 second, FH=family history, 
GFR=glomerular filtration rate, HDL=high density lipoprotein, HF=heart failure, HOMA-IR= homeostatic model assessment of insulin resistance, IHD=ischemic heart 
disease, LDL=low-density lipoprotein, LVH=left ventricular hypertrophy, MH=metabolically health, MI=myocardial infarction, MUH=metabolically unhealthy, 
NA=not available SBP=systolic blood pressure, WHI=Women’s Health Initiative, WHR= waist-to-hip ratio 
Supplementary Table 5. Table of RRs and 95% CIs from nonlinear dose-response analysis of 
BMI and atrial fibrillation 
 
 Atrial fibrillation 
BMI RR (95% CI) 
15.0 0.98 (0.90-1.06) 
17.5 0.96 (0.93-1.00) 
20.0 1.00 
22.5 1.09 (1.04-1.13) 
25.0 1.21 (1.13-1.31) 
27.5 1.39 (1.25-1.56) 
30.0  1.63 (1.40-1.89) 
32.5 1.93 (1.60-2.32) 
35.0 2.32 (1.86-2.90) 
37.5 2.82 (2.18-3.66) 
40.0 3.45 (2.56-4.64) 
 
 
 
 
 
 
 
 
Supplementary Table 6. Table of RRs and 95% CIs from nonlinear dose-response analysis of 
waist circumference and atrial fibrillation 
 
Men  
WC RR (95% CI) 
76 cm 1.00 
80 1.01 (0.89-1.15) 
85 1.07 (0.85-1.35) 
90 1.18 (0.88-1.57) 
95 1.34 (0.97-1.84) 
100 1.55 (1.13-2.14) 
105 1.84 (1.36-2.49) 
110 2.22 (1.69-2.92) 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 7. Table of summary relative risks (95% CIs) from the current meta-
analysis 
Adiposity variable N Increment  Summary RR (95% CI) I
2
 pheterogeneity 
BMI 25 5 kg/m
2 
1.28 (1.20-1.38) 97% <0.0001 
Waist circumference 5 10 cm 1.18 (1.12-1.25) 73% 0.005 
Waist-to-hip ratio 4 0.1 units 1.09 (1.02-1.16) 44% 0.15 
Hip circumference 3 10 cm 1.32 (1.16-1.51) 91% <0.0001 
Weight 10 5 kg 1.10 (1.08-1.13) 74% <0.0001 
Weight gain 2 5 kg 1.08 (0.97-1.19) 86% 0.007 
Body fat mass 4 5 kg 1.09 (1.02-1.16) 94% <0.0001 
Body fat percentage 3 10% 1.10 (0.92-1.33) 90% <0.0001 
 
 
Supplementary Figure 1. Funnel plot for BMI and atrial fibrillation incidence 
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Moose checklist 
 
Reporting of background should include Page  
Problem definition 3-4 
Hypothesis statement 4 
Description of study outcome(s) 3-4, 5 
Type of exposure or intervention used 3-4, 5 
Type of study designs used 3-4, 5 
Study population 5, Supplementary Table 4 
  
Reporting of search strategy should include 
 
Qualifications of searchers (eg, librarians and investigators) 5, Investigators 
Search strategy, including time period included in the synthesis 
and keywords 
Supplementary Table 1 and 
2 
Effort to include all available studies, including contact with 
authors 
No contact with authors 
Databases and registries searched 5 
Search software used, name and version, including special 
features used (eg, explosion) 
5, Supplementary Table 1 
and 2 
Use of hand searching (eg, reference lists of obtained articles) 5 
List of citations located and those excluded, including 
justification 
Supplementary Table 3 
Method of addressing articles published in languages other than 
English 
5, only English language 
publications were included 
Method of handling abstracts and unpublished studies 5, not included 
Description of any contact with authors No contact with authors 
  
Reporting of methods should include 
Description of relevance or appropriateness of studies assembled 
for assessing the hypothesis to be tested 
5-6 
Rationale for the selection and coding of data (eg, sound clinical 
principles or convenience) 
5-6 
Documentation of how data were classified and coded (eg, 
multiple raters, blinding, and interrater reliability) 
6 
Assessment of confounding (eg, comparability of cases and 
controls in studies where appropriate) 
Table 1, Supplementary 
Table 4 
Assessment of study quality, including blinding of quality 
assessors; stratification or regression on possible predictors of 
study results 
5, 11, Table 1 
Assessment of heterogeneity  7 
Description of statistical methods (eg, complete description of 
fixed or random effects models, justification of whether the 
chosen models account for predictors of study results, dose-
response models, or cumulative meta-analysis) in sufficient detail 
to be replicated 
6-7 
Provision of appropriate tables and graphics 8-11, Supplementary Table 
1-4 
  
Reporting of results should include 
Graphic summarizing individual study estimates and overall 
estimate 
8-11, Figure 2-5, Table 1 
Table giving descriptive information for each study included Supplementary Table 4 
Results of sensitivity testing (eg, subgroup analysis) 10-11, Table 1 
Indication of statistical uncertainty of findings 
 
8-11 
  
Reporting of discussion should include 
Quantitative assessment of bias (eg, publication bias) 14 
Justification for exclusion (eg, exclusion of non–English-
language citations) 
No relevant non-English 
publications were identified 
Assessment of quality of included studies 15 
  
Reporting of conclusions should include 
Consideration of alternative explanations for observed results 13-14 
Generalization of the conclusions (ie, appropriate for the data 
presented and within the domain of the literature review) 
14-15 
Guidelines for future research 15 
Disclosure of funding source 16 
 
 
 
